受强制性开放获取政策约束的文章 - Suhendan Ekmekcioglu了解详情
无法在其他位置公开访问的文章：3 篇
Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human …
M Zheng, D Bocangel, R Ramesh, S Ekmekcioglu, N Poindexter, ...
Molecular cancer therapeutics 7 (12), 3842-3851, 2008
强制性开放获取政策： US National Institutes of Health
Mitochondrial dynamic alterations regulate melanoma cell progression
F Dal Yontem, SH Kim, Z Ding, E Grimm, S Ekmekcioglu, H Akcakaya
Journal of cellular biochemistry 120 (2), 2098-2108, 2019
强制性开放获取政策： US National Institutes of Health
Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells
S Ekmekcioglu, C Chattopadhyay*, U Akar*, A Gabisi Jr, RA Newman, ...
Nutrition and cancer 63 (6), 940-949, 2011
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：37 篇
Oncogenic BRAF (V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma
JS Khalili, S Liu, TG Rodríguez-Cruz, M Whittington, S Wardell, C Liu, ...
Clinical Cancer Research 18 (19), 5329-5340, 2012
强制性开放获取政策： US National Institutes of Health
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
JA Ellerhorst, VR Greene, S Ekmekcioglu, CL Warneke, MM Johnson, ...
Clinical Cancer Research 17 (2), 229-235, 2011
强制性开放获取政策： US National Institutes of Health
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Y Hailemichael, DH Johnson, N Abdel-Wahab, WC Foo, SE Bentebibel, ...
Cancer Cell 40 (5), 509-523. e6, 2022
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
P Bailey, DK Chang, MA Forget, FAS Lucas, HA Alvarez, C Haymaker, ...
Scientific reports 6 (1), 35848, 2016
强制性开放获取政策： Cancer Research UK, Wellcome Trust, Pancreatic Cancer, UK
Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy
AG Sikora, A Gelbard, MA Davies, D Sano, S Ekmekcioglu, J Kwon, ...
Clinical cancer research 16 (6), 1834-1844, 2010
强制性开放获取政策： US National Institutes of Health
Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy
SH Kim, J Roszik, EA Grimm, S Ekmekcioglu
Frontiers in oncology 8, 67, 2018
强制性开放获取政策： US National Institutes of Health
Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2
E Lopez-Rivera, P Jayaraman, F Parikh, MA Davies, S Ekmekcioglu, ...
Cancer research 74 (4), 1067-1078, 2014
强制性开放获取政策： US National Institutes of Health
Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma
Y Qin, S Ekmekcioglu, P Liu, LM Duncan, G Lizée, N Poindexter, ...
Molecular Cancer Research 9 (11), 1537-1550, 2011
强制性开放获取政策： US National Institutes of Health
Cell surface CD74–MIF interactions drive melanoma survival in response to interferon-γ
K Tanese, Y Hashimoto, Z Berkova, Y Wang, F Samaniego, JE Lee, ...
Journal of Investigative Dermatology 135 (11), 2775-2784, 2015
强制性开放获取政策： US National Institutes of Health
Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target
EA Grimm, AG Sikora, S Ekmekcioglu
Clinical Cancer Research 19 (20), 5557-5563, 2013
强制性开放获取政策： US National Institutes of Health
Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis
EA Grimm, J Ellerhorst, CH Tang, S Ekmekcioglu
Nitric oxide 19 (2), 133-137, 2008
强制性开放获取政策： US National Institutes of Health
The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment
H Zhou, S Ekmekcioglu, JW Marks, KA Mohamedali, K Asrani, KK Phillips, ...
Journal of Investigative Dermatology 133 (4), 1052-1062, 2013
强制性开放获取政策： US National Institutes of Health
Dual roles of RNF2 in melanoma progression
K Rai, KC Akdemir, LN Kwong, P Fiziev, CJ Wu, EZ Keung, S Sharma, ...
Cancer discovery 5 (12), 1314-1327, 2015
强制性开放获取政策： US National Institutes of Health
The COX2 effector microsomal PGE2 synthase 1 is a regulator of immunosuppression in cutaneous melanoma
SH Kim, J Roszik, SN Cho, D Ogata, DR Milton, W Peng, DG Menter, ...
Clinical Cancer Research 25 (5), 1650-1663, 2019
强制性开放获取政策： US National Institutes of Health
Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma
S Ekmekcioglu, MA Davies, K Tanese, J Roszik, M Shin-Sim, ...
Clinical Cancer Research 22 (12), 3016-3024, 2016
强制性开放获取政策： US National Institutes of Health
Hypoxia-driven mechanism of vemurafenib resistance in melanoma
Y Qin, J Roszik, C Chattopadhyay, Y Hashimoto, C Liu, ZA Cooper, ...
Molecular cancer therapeutics 15 (10), 2442-2454, 2016
强制性开放获取政策： US National Institutes of Health
The role of melanoma tumor‐derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10
K Tanese, EA Grimm, S Ekmekcioglu
International journal of cancer 131 (4), 891-901, 2012
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定